JPWO2019199476A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019199476A5 JPWO2019199476A5 JP2020555099A JP2020555099A JPWO2019199476A5 JP WO2019199476 A5 JPWO2019199476 A5 JP WO2019199476A5 JP 2020555099 A JP2020555099 A JP 2020555099A JP 2020555099 A JP2020555099 A JP 2020555099A JP WO2019199476 A5 JPWO2019199476 A5 JP WO2019199476A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- buffer
- filtration
- chromatography
- ultrafiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024056116A JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656687P | 2018-04-12 | 2018-04-12 | |
| US62/656,687 | 2018-04-12 | ||
| PCT/US2019/024683 WO2019199476A1 (en) | 2018-04-12 | 2019-03-28 | Methods for making stable protein compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056116A Division JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521119A JP2021521119A (ja) | 2021-08-26 |
| JP2021521119A5 JP2021521119A5 (https=) | 2022-03-30 |
| JPWO2019199476A5 true JPWO2019199476A5 (https=) | 2022-03-30 |
| JP7465215B2 JP7465215B2 (ja) | 2024-04-10 |
Family
ID=66251859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555099A Active JP7465215B2 (ja) | 2018-04-12 | 2019-03-28 | 安定なタンパク質組成物を製造する方法 |
| JP2024056116A Pending JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056116A Pending JP2024075786A (ja) | 2018-04-12 | 2024-03-29 | 安定なタンパク質組成物を製造する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210163531A1 (https=) |
| EP (1) | EP3774894A1 (https=) |
| JP (2) | JP7465215B2 (https=) |
| KR (1) | KR102791798B1 (https=) |
| CN (1) | CN111971302A (https=) |
| AU (2) | AU2019250882B2 (https=) |
| BR (1) | BR112020020854A2 (https=) |
| CA (1) | CA3096374A1 (https=) |
| CL (1) | CL2020002597A1 (https=) |
| EA (1) | EA202092464A1 (https=) |
| IL (1) | IL277797B1 (https=) |
| MA (1) | MA52204A (https=) |
| MX (2) | MX2020010724A (https=) |
| SG (1) | SG11202010100QA (https=) |
| WO (1) | WO2019199476A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150210753A1 (en) | 2012-07-26 | 2015-07-30 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| AU2020381536A1 (en) * | 2019-11-13 | 2022-04-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
| WO2021252782A1 (en) * | 2020-06-11 | 2021-12-16 | 2Seventy Bio, Inc. | Methods for manufacturing viral vectors |
| US12286451B2 (en) | 2020-11-23 | 2025-04-29 | Medtech Products Inc. | Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers |
| US20240101679A1 (en) * | 2020-12-09 | 2024-03-28 | Dr. Reddy’S Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
| WO2024165043A1 (en) * | 2023-02-08 | 2024-08-15 | Beigene Switzerland Gmbh | Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff) |
| CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
| CN121587349A (zh) * | 2026-01-28 | 2026-03-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | 高浓度无菌乳铁蛋白液及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005323489A1 (en) * | 2004-05-10 | 2006-07-13 | Curagen Corporation | Prophylactic and therapeutic uses of FGF-20 in radiation protection |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| CN101098889A (zh) | 2004-11-05 | 2008-01-02 | 盘林京有限公司 | 抗体导致的细胞膜损伤 |
| AU2006270009A1 (en) | 2005-07-18 | 2007-01-25 | Amgen Inc. | Human anti-B7RP1 neutralizing antibodies |
| US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| ES2650224T3 (es) | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| US20130195888A1 (en) * | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| TWI543768B (zh) * | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| HUE025670T2 (en) * | 2009-03-03 | 2016-04-28 | Grifols Therapeutics Inc | A method for producing plasminogen |
| AU2010202125B1 (en) * | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| CA2810731A1 (en) * | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph |
| AU2012250924B2 (en) * | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| ES2381828B1 (es) * | 2012-03-20 | 2012-11-16 | Grifols, S.A. | PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO |
| US20140154270A1 (en) * | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
| AU2014205441B2 (en) * | 2013-01-09 | 2019-12-12 | Takeda Pharmaceutical Company Limited | Methods for purification of arylsulfatase A |
| CA2906737C (en) | 2013-03-15 | 2023-08-15 | Amgen Inc. | Human pac1 antibodies |
| EP3102603A1 (en) * | 2014-02-07 | 2016-12-14 | Novo Nordisk A/S | Antibody process |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| SG11201901081XA (en) * | 2016-08-17 | 2019-03-28 | Boehringer Ingelheim Int | Process for the preparation of highly concentrated liquid formulations containing biomolecules |
| GB201707484D0 (en) * | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| GB2636539A (en) * | 2023-03-16 | 2025-06-25 | Univ Of Sunderland | Wound dressing |
-
2019
- 2019-03-28 KR KR1020207032156A patent/KR102791798B1/ko active Active
- 2019-03-28 BR BR112020020854-0A patent/BR112020020854A2/pt unknown
- 2019-03-28 MA MA052204A patent/MA52204A/fr unknown
- 2019-03-28 SG SG11202010100QA patent/SG11202010100QA/en unknown
- 2019-03-28 IL IL277797A patent/IL277797B1/en unknown
- 2019-03-28 EP EP19719397.2A patent/EP3774894A1/en active Pending
- 2019-03-28 AU AU2019250882A patent/AU2019250882B2/en active Active
- 2019-03-28 WO PCT/US2019/024683 patent/WO2019199476A1/en not_active Ceased
- 2019-03-28 EA EA202092464A patent/EA202092464A1/ru unknown
- 2019-03-28 CN CN201980025383.9A patent/CN111971302A/zh active Pending
- 2019-03-28 JP JP2020555099A patent/JP7465215B2/ja active Active
- 2019-03-28 US US17/046,662 patent/US20210163531A1/en active Pending
- 2019-03-28 MX MX2020010724A patent/MX2020010724A/es unknown
- 2019-03-28 CA CA3096374A patent/CA3096374A1/en active Pending
-
2020
- 2020-10-08 CL CL2020002597A patent/CL2020002597A1/es unknown
- 2020-10-09 MX MX2025009986A patent/MX2025009986A/es unknown
-
2024
- 2024-03-29 JP JP2024056116A patent/JP2024075786A/ja active Pending
-
2026
- 2026-01-14 AU AU2026200233A patent/AU2026200233A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521119A5 (https=) | ||
| JPWO2019199476A5 (https=) | ||
| ES2673022T3 (es) | Una formulación líquida de conjugado de hormona de crecimiento humano de acción prolongada | |
| JP4785816B2 (ja) | 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法 | |
| JP4536829B2 (ja) | モノクローナル抗体又はポリクローナル抗体の安定な凍結乾燥された医薬製剤 | |
| AU2026200233A1 (en) | Methods for making stable protein compositions | |
| JP2020079242A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| EP3071181B1 (en) | Pharmaceutical composition of an anti-vegf antibody | |
| JP2019504882A (ja) | Ｖｅｇｆアンタゴニストの液体製剤 | |
| US20210138070A1 (en) | Formulation of long-acting human growth hormone immunoglobulin conjugate | |
| JPWO2002098445A1 (ja) | タンパク質製剤 | |
| US20230414760A1 (en) | Pharmaceutical formulation | |
| EP3138575A1 (en) | Freeze-dried hgf preparation | |
| TWI617324B (zh) | 高度濃縮之長效人類生長激素共軛物之液體製劑 | |
| US20200390705A1 (en) | Method for reducing the reconstitution time of spray-dried protein formulations | |
| CN102670522B (zh) | 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备 | |
| JP2022513142A (ja) | タンパク質処理のための賦形剤化合物 | |
| JP2015535238A (ja) | ペグインターフェロンα−２ｂの安定な医薬組成物 | |
| US20240287185A1 (en) | Formulations of anti-pd1 antibodies | |
| US20220313792A1 (en) | Hemoglobin-based nanoparticles for oxygen delivery | |
| US20180256722A1 (en) | Stable aqueous formulation for growth hormone | |
| JP3421330B2 (ja) | ビダラビン注射用乾燥製剤 | |
| CN117461624A (zh) | 一种稳定的外泌体质控品及其冻干方法 | |
| Prasad et al. | Innovation in stabilization of biopharmaceuticals | |
| MXPA01002206A (en) | Stabilized granulocyte colony stimulating factor |